Table 2.
Sample |
Measure-ment |
Outcome |
PBMS predictor set |
||
---|---|---|---|---|---|
point |
|
intention estimate |
domains |
sub-domains |
|
1 predictor | 3 predictors | 6 predictors | |||
|
pre total n = 50 |
r2 |
.55(.54)* |
.60(.57)* |
.69(.65)* |
Pre-test |
pre sub s. n = 19 |
r2 |
.34(.31)* |
.38(.30) |
.56*(.42) |
|
post sub s. n = 19 |
r2 |
.65(.63)* |
.68(.61)* |
.73(59)* |
|
pre total n = 177 |
r2 |
.41(41)* |
.43(41)* |
.50(48)* |
RCT |
post total n = 177 |
r2 |
.61(61)* |
.63(62)* |
.68(67)* |
|
post CG n = 88 |
r2 |
.56(.56)* |
.56(.55)* |
.64(61)* |
post IG n = 89 | r2 | .69(69)* | .74(73)* | .78(76)* |
The table shows R-square(corrected R-square) values (indicating the percentage of explained variance) from predicting the criterion intention to use DMT (disease modifying therapy) using various predictor sets drawn from the PBMS in regression analyses.”*” = significance level <0.01. The pre-test sub sample (n = 19) includes participants of the PEPADIP pilot course who completed the PBMS twice (pre & post). RCT=randomized controlled trial.